Bicycle Therapeutics plc (NASDAQ:BCYC) CAO Travis Alvin Thompson Sells 2,686 Shares of Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) CAO Travis Alvin Thompson sold 2,686 shares of Bicycle Therapeutics stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $15.00, for a total transaction of $40,290.00. Following the completion of the sale, the chief accounting officer now directly owns 32,146 shares in the company, valued at approximately $482,190. This represents a 7.71 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Travis Alvin Thompson also recently made the following trade(s):

• On Thursday, January 2nd, Travis Alvin Thompson sold 1,750 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $14.09, for a total transaction of $24,657.50.
• On Monday, November 11th, Travis Alvin Thompson sold 6,256 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $25.11, for a total transaction of $157,088.16.

Bicycle Therapeutics Price Performance

NASDAQ BCYC opened at $14.88 on Tuesday. Bicycle Therapeutics plc has a 1 year low of $12.17 and a 1 year high of $28.67. The stock has a market capitalization of $1.03 billion, a PE ratio of -4.52 and a beta of 0.92. The company’s 50 day simple moving average is $19.27 and its two-hundred day simple moving average is $21.86.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.04. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The business had revenue of $2.68 million for the quarter, compared to analysts’ expectations of $6.82 million. During the same period in the prior year, the company posted ($1.26) EPS. The business’s revenue for the quarter was down 50.0% compared to the same quarter last year. On average, research analysts anticipate that Bicycle Therapeutics plc will post -3.05 EPS for the current year.

Wall Street Analyst Weigh In

BCYC has been the subject of several research reports. JMP Securities cut their price target on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a research note on Wednesday, December 18th. B. Riley cut their target price on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Stephens began coverage on shares of Bicycle Therapeutics in a research report on Friday, November 8th. They issued an “equal weight” rating and a $25.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Bicycle Therapeutics in a report on Thursday, October 31st. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $35.00 target price on shares of Bicycle Therapeutics in a report on Friday, November 1st. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.25.

Institutional Trading of Bicycle Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. lifted its stake in Bicycle Therapeutics by 26.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock worth $191,000 after purchasing an additional 1,782 shares in the last quarter. Principal Financial Group Inc. purchased a new stake in Bicycle Therapeutics in the 3rd quarter worth approximately $10,028,000. Geode Capital Management LLC increased its holdings in shares of Bicycle Therapeutics by 79.3% in the 3rd quarter. Geode Capital Management LLC now owns 38,335 shares of the company’s stock worth $868,000 after buying an additional 16,958 shares during the last quarter. Jane Street Group LLC increased its holdings in shares of Bicycle Therapeutics by 35.7% in the 3rd quarter. Jane Street Group LLC now owns 20,180 shares of the company’s stock worth $457,000 after buying an additional 5,310 shares during the last quarter. Finally, State Street Corp increased its holdings in shares of Bicycle Therapeutics by 233.5% in the 3rd quarter. State Street Corp now owns 86,271 shares of the company’s stock worth $1,952,000 after buying an additional 60,399 shares during the last quarter. 86.15% of the stock is currently owned by hedge funds and other institutional investors.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.